Key result
Adipose tissue browning demonstrates preclinical hepatoprotective benefits in MASLD, though human evidence remains limited.
Why the study?
MASLD is an increasingly prevalent complication of obesity with limited therapies targeting upstream drivers, making adipose tissue browning a potential therapeutic mechanism of interest.
Answers are grounded in this paper and cite their sources.
Adipose tissue browning shows preclinical promise for treating MASLD by modulating lipid metabolism and inflammation, though human translation remains limited.
Purpose of Review Metabolic dysfunction–associated steatotic liver disease (MASLD) is an increasingly prevalent complication of obesity and metabolic dysregulation, with limited therapies targeting upstream drivers of disease. Adipose tissue has emerged as a central regulator of systemic metabolic homeostasis, where dysfunction contributes to excess free fatty acid flux, chronic inflammation, and hepatic steatosis. In this context, adipose tissue browning—the induction of thermogenically active beige adipocytes within white adipose depots—has gained attention as a potential therapeutic mechanism. Recent Findings Recent advances highlight that adipose browning modulates multiple pathways relevant to MASLD. These include enhanced mitochondrial β-oxidation and energy expenditure, leading to reduced lipid delivery to the liver, as well as endocrine signaling mediated by batokines such as fibroblast growth factor 21 (FGF21), irisin, and neuregulin 4 (Nrg4). Collectively, these pathways influence hepatic lipid metabolism, insulin sensitivity, and inflammatory and fibrotic processes. The preclinical studies consistently demonstrate metabolic and hepatoprotective benefits of browning; however, translational evidence in humans remains limited and heterogeneous. Factors such as reduced thermogenic capacity in obesity, inter-individual variability, and challenges in sustaining browning activation constrain clinical applicability. Summary Overall, adipose tissue browning represents a promising component of a systems-based approach to MASLD. Future work should focus on integrating mechanistic insights with clinical investigation to clarify its therapeutic potential and to identify strategies that enable durable and patient-specific metabolic benefits.
No takes yet. Share an insight, caveat, or question.
Guerrero et al. (2026) conducted a review in Metabolic dysfunction–associated steatotic liver disease (MASLD). Adipose tissue browning was evaluated. Adipose tissue browning modulates multiple pathways relevant to MASLD, demonstrating preclinical hepatoprotective benefits, though translational evidence in humans remains limited.
Synapse has enriched 10 related papers. Consider them for comparative context: